このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cidara Therapeutics マネジメント

マネジメント基準チェック /24

Cidara Therapeutics'の CEO はJeff Steinで、 Jan2014年に任命され、の在任期間は 10.42年です。の年間総報酬は$ 1.56Mで、 38.1%給与と61.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.6%を直接所有しており、その価値は$ 916.34K 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と3.4年です。

主要情報

Jeff Stein

最高経営責任者

US$1.6m

報酬総額

CEO給与比率	38.1%
CEO在任期間	10.4yrs
CEOの所有権	1.6%
経営陣の平均在職期間	3.6yrs
取締役会の平均在任期間	3.4yrs

経営陣の近況

Recent updates

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Sep 28

Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Apr 17

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

Mar 25

Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M

Aug 09

Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts

Dec 17

Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic

Aug 17

Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?

Aug 04

Cidara Therapeutics: Rezafungin Data Could Bring Value

Jul 20

CEO報酬分析

Cidara Therapeutics の収益と比較して、Jeff Stein の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$36m
Dec 31 2023	US$2m	US$594k	-US$23m
Sep 30 2023	n/a	n/a	-US$35m
Jun 30 2023	n/a	n/a	-US$15m
Mar 31 2023	n/a	n/a	-US$13m
Dec 31 2022	US$1m	US$566k	-US$34m
Sep 30 2022	n/a	n/a	-US$33m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$44m
Dec 31 2021	US$2m	US$566k	-US$42m
Sep 30 2021	n/a	n/a	-US$47m
Jun 30 2021	n/a	n/a	-US$47m
Mar 31 2021	n/a	n/a	-US$74m
Dec 31 2020	US$1m	US$542k	-US$75m
Sep 30 2020	n/a	n/a	-US$67m
Jun 30 2020	n/a	n/a	-US$47m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$1m	US$526k	-US$41m
Sep 30 2019	n/a	n/a	-US$39m
Jun 30 2019	n/a	n/a	-US$56m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$1m	US$501k	-US$69m
Sep 30 2018	n/a	n/a	-US$70m
Jun 30 2018	n/a	n/a	-US$69m
Mar 31 2018	n/a	n/a	-US$59m
Dec 31 2017	US$2m	US$460k	-US$56m

報酬と市場: Jeffの総報酬 ($USD 1.56M ) は、 US市場 ($USD 678.50K ) の同規模の企業の平均を上回っています。

報酬と収益: Jeffの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Jeff Stein (69 yo)

10.4yrs

在職期間

US$1,558,544

報酬

Dr. Jeffrey L. Stein, Ph D., also known as Jeff, has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein served as Principal Financ...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jeffrey Stein	President	10.4yrs	US$1.56m	1.6% $ 845.7k
Shane Ward	Chief Legal Officer	2.8yrs	US$929.86k	0.11% $ 59.7k
Taylor Sandison	Chief Medical Officer	7.8yrs	US$884.09k	0.24% $ 128.0k
Kevin Forrest	Founder and Chief Strategy Officer	no data	US$613.24k	データなし
Preetam Shah	CFO, Chief Business Officer & Principal Accounting Officer	2.8yrs	US$683.71k	0.16% $ 87.3k
Allison Lewis	Senior Vice President of People & Culture	3.4yrs	データなし	データなし
Leslie Tari	Chief Scientific Officer	5.3yrs	US$1.39m	0.15% $ 77.6k
Laura Navalta	Senior Vice President of Clinical Operations	3.8yrs	データなし	データなし
Nicole Davarpanah	Senior VP of Translational Research & Development	less than a year	データなし	データなし

3.6yrs

平均在職期間

51.5yo

平均年齢

経験豊富な経営陣: CDTXの経営陣は経験豊富であると考えられます ( 3.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jeffrey Stein	President	10.4yrs	US$1.56m	1.6% $ 845.7k
Daniel Burgess	Independent Chairman of the Board	10.2yrs	US$126.84k	0.0033% $ 1.7k
Theodore Schroeder	Independent Director	10.2yrs	US$98.84k	0% $ 0
Bonnie Bassler	Independent Director	3.4yrs	US$86.84k	0.00033% $ 174.9
Carin Canale-Theakston	Independent Director	3.4yrs	US$82.34k	0% $ 0
Chrysa Mineo	Independent Director	6.3yrs	US$91.34k	0% $ 0
Stephen Schoenberger	Member of the Scientific Advisory Board	less than a year	データなし	データなし
Perry Nisen	Member of the Scientific Advisory Board	2.1yrs	データなし	データなし
Ryan Spencer	Independent Director	less than a year	データなし	データなし
James Merson	Independent Director	less than a year	データなし	データなし
Laura Tadvalkar	Independent Director	less than a year	データなし	データなし

3.4yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: CDTXの取締役会は経験豊富であると考えられます ( 3.4年の平均在任期間)。

Cidara Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Cidara Therapeutics, Inc., Annual General Meeting, Jul 18, 2024

Cidara Therapeutics, Inc. Appoints Nicole Davarpanah as Senior Vice President of Translational Research and Development

High number of new directors

Cidara Therapeutics, Inc. Announces Executive Changes

High number of new directors

Cidara Therapeutics, Inc. Announces Executive Changes

Recent updates

Cidara Therapeutics, Inc., Annual General Meeting, Jul 18, 2024

Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules

Napp Pharmaceutical Group Ltd. acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc. (NasdaqCM:CDTX).

Cidara Therapeutics, Inc. announced that it expects to receive $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors

Cidara Therapeutics, Inc. announced delayed annual 10-K filing

Cidara Therapeutics, Inc. Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China

Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id

Cidara Therapeutics Requests a Hearing Before the Nasdaq Hearings Panel

Consensus estimates of losses per share improve by 21%

New minor risk - Profitability

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cidara Therapeutics and Mundipharma Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive Candidiasis in Adults

Cidara Therapeutics, Inc. Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

New major risk - Financial position

Cidara Therapeutics, Inc. Appoints Nicole Davarpanah as Senior Vice President of Translational Research and Development

Consensus revenue estimates fall by 30%

New minor risk - Profitability

Forecast to breakeven in 2025

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Cidara Therapeutics Provides Update on REZZAYO™ (Rezafungin for Injection)

Cidara Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B

New minor risk - Market cap size

Cidara Therapeutics, Inc. to Present Highlights from Its Ongoing Preclinical Studies of CD421 as Well as the Development of Its Novel Drug-Fc Conjugates from Cidara’s Cloudbreak® Platform

Consensus revenue estimates increase by 85%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

Full year 2022 earnings: EPS misses analyst expectations

Forecast to breakeven in 2023

We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Price target decreased to US$5.50

Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from Its Cloudbreak Platform

Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet

High number of new directors

Consensus revenue estimates increase by 67%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cidara Therapeutics Attends Hearing Before the Nasdaq Hearings Panel and Presents Plan to Regain Compliance with the Nasdaq Capital Market

Cidara spikes on $11M milestone payment from partner Mundipharma

Cidara Therapeutics, Inc. Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Cidara Therapeutics Announces Initiation of Phase 2A Human Viral Challenge Trial to Evaluate Cd388 for Universal Prevention of Influenza

Cidara begins dosing of antiviral CD388 in trial for preventing influenza

Cidara Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 53%

Second quarter 2022 earnings: EPS exceeds analyst expectations

Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M

Cidara Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$5.67

High number of new directors

Mundipharma and Cidara Therapeutics Announces First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrating its Positive Efficacy and Safety Profile

Cidara Therapeutics, Inc. Announces Executive Changes

Cidara Therapeutics, Inc. Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza

Consensus revenue estimates increase by 44%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Medicines and Healthcare Products Regulatory Agency in the UK Grants Mundipharma and Cidara Therapeutics Inc.'s Rezafungin Promising Innovative Medicine Designation

Cidara Therapeutics, Inc. Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza

Price target increased to US$6.25

Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts

Cidara Therapeutics, Inc. and Mundipharma Announce Positive Topline Results from Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for Treatment of Candidemia and Invasive Candidiasis

President recently bought US$80k worth of stock

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.41 loss in 3Q 2020)

Price target decreased to US$6.00

President recently bought US$87k worth of stock

マネジメント基準チェック /24